Partner David Rosen provides an overview of the Food and Drug Administration’s increasing use of consent decrees as compliance enforcement tools, stating that companies can potentially improve their manufacturing operations and systems quality by efficiently meeting the terms and conditions of a consent decree. He adds that entering into a consent decree requires significant time and resources, but notes that companies can better meet these requirements by proactively investing in a comprehensive quality program.
Click here to read the complete article.
Author(s)
Related Insights
21 October 2024
Events
Legal Overview of the BIOSECURE Act
Foley special counsel John Strom is speaking in the Association for Accessible Medicine’s GRx+Biosims 2024 conference in a panel titled “Legal Overview of the BIOSECURE Act” on October 21.
04 October 2024
Innovative Technology Insights
Decoding California’s Recent Flurry of AI Laws
Governor Newsom signed over 18 AI-related bills into law during September, impacting numerous industries.
17 October 2024
Events
Top Compliance Considerations when Commercializing in the U.S.
Kyle Faget and Nathan "Nate" Beaver, co-chair of Foley's Medical Device and Equipment Area of Focus within the firm's Health Care & Life Sciences Sector, invite you to join us for a webinar on the compliance considerations you need to know when you are commercializing your medical device products in the U.S.